Shanghai-based cancer drugmaker Abbisko lines up $42M B round as it makes a leap for the clinic

Qiming Ventures is leading a B round for Abbisko Therapeutics, more than doubling the Shanghai-based biotech’s previous haul as it hustles a pair of homegrown cancer drugs toward an IND.